<DOC>
	<DOCNO>NCT00117598</DOCNO>
	<brief_summary>This open-label , randomized trial relapse refractory subject mantle cell lymphoma ( MCL ) .</brief_summary>
	<brief_title>Study Evaluating Temsirolimus ( CCI-779 ) In Mantle Cell Lymphoma ( MCL )</brief_title>
	<detailed_description />
	<mesh_term>Lymphoma</mesh_term>
	<mesh_term>Lymphoma , Mantle-Cell</mesh_term>
	<mesh_term>Everolimus</mesh_term>
	<mesh_term>Sirolimus</mesh_term>
	<criteria>Mantle cell lymphoma ( MCL ) confirm histology , immunophenotype , cyclin D1 analysis Received 2 7 prior therapy may include hematopoietic stem cell transplant ( i.e . induction + consolidation + maintenance ) Prior treatment alkylating agent anthracycline , rituximab , individually combination , status least one following : Primary disease refractory least 2 regimen ; Refractory least 1 regimen first relapse ; Refractory untreated second great relapse ; Refractory first line relapse second line . Chemotherapy combination may include , limited : CHOP ( Cyclophosphamide , doxorubicin , vincristine , prednisone ) , RCHOP ( Rituximab , Cyclophosphamide , doxorubicin , vincristine , prednisone ) , FCM ( Fludarabine , cyclophosphamide , mitoxantrone ) , RFCM ( Rituximab , Fludarabine , cyclophosphamide , mitoxantrone ) , ICE ( Ifosfamide , carboplatin , etoposide ) , DHAP ( Dexamethasone , cisplatin , cytarabine ) hyperCVAD ( Cyclophosphamide , doxorubicin , vincristine , dexamethasone ) . Subjects less equal six month allogeneic hematopoietic stem cell transplant immunosuppressive therapy evidence graft versus host disease Prior investigational therapy within 3 week first dose . Investigational therapy define treatment approved indication . Active central nervous system ( CNS ) metastases , indicate clinical symptom , cerebral edema , requirement corticosteroid and/or progressive growth . ( Treated CNS metastasis must stable &gt; 2 week prior Day 1 . )</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2015</verification_date>
	<keyword>Lymphoma</keyword>
</DOC>